NOVT NOVANTA INC 10-Q 2026-10-02 section summaries

Novanta Inc. (NOVT) — Q3 and nine months ended October 2, 2026

Results

Revenue accelerated in Q3, but higher operating expenses and acquisition-related costs sharply reduced earnings. Q3 operating income fell despite higher gross profit; net income was further pressured by a higher effective tax rate. For the nine-month period, revenue and gross profit grew, while operating income and net income were slightly lower than a year earlier.

Q3 gross margin was 44.5% versus 44.8%; the 9M margin was 44.7% versus 44.6%. Q3 operating expenses rose to $121.727 million from $89.073 million. Restructuring, acquisition and related costs were $23.086 million versus $6.677 million in Q3, and $38.190 million versus $16.794 million for 9M. Acquisition-related charges accounted for $19.219 million of Q3 costs and $28.126 million for 9M. Purchased-intangible amortization in operating expenses was $14.679 million in Q3 versus $6.928 million; total amortization was $21.408 million versus $11.180 million. The Q3 effective tax rate rose to 68.2% from 32.4%, chiefly reflecting non-deductible acquisition costs and income mix; the 9M rate was 26.6% versus 24.2%.

Revenue and segment performance

Advanced Surgical Technologies was the standout growth area, including Riverpoint Medical’s minimally invasive surgical consumables. Precision Medicine declined in Q3 despite 9M growth.

Medical Solutions’ faster Q3 revenue growth did not translate into segment operating-income growth; its depreciation and amortization increased to $21.695 million from $9.530 million. Higher unallocated costs offset segment profit growth. Both segments primarily serve OEM customers; Automation Enabling Technologies serves industrial, robotics, life-sciences and medical-laser applications, while Medical Solutions supplies surgical, imaging/RFID and operating-room technologies.

Riverpoint acquisition, financing and dilution

Novanta acquired Riverpoint Medical on July 23, 2026, for $1,200.6 million net of cash acquired. The preliminary purchase allocation included $792.2 million of goodwill and $756.0 million of identifiable intangibles—customer relationships ($570.0 million, 16-year life), developed technologies ($170.0 million, 10 years) and trade name ($16.0 million, 10 years). The goodwill is not tax-deductible. Riverpoint contributed $32.9 million of revenue and a $2.3 million pretax loss, including acquired-intangible amortization and milestone accretion. A further $250.0 million milestone payment is due on or before January 8, 2027; its acquisition-date present value was $244.1 million. The preliminary allocation may change. Pro forma results assuming acquisition on January 1, 2025 were Q3 revenue of $312.0 million and net income of $13.7 million (Q3 2025: $285.7 million and $4.4 million); 9M revenue of $906.9 million and net income of $33.5 million (9M 2025: $821.4 million and a $16.8 million loss). These are not reported results.

The June 2026 private placement issued 2.143 million shares at $140 per share for $300 million gross and approximately $288 million net proceeds. Shares outstanding increased from 35.671 million at December 31, 2025 to 37.820 million at October 2, 2026. Weighted-average diluted shares were 42.709 million in Q3 and 41.486 million for 9M, versus 36.040 million and 36.082 million, respectively. The calculation includes at least 4.7 million shares issuable under tangible equity-unit purchase contracts. Share-based compensation was $29.697 million for 9M versus $21.296 million; a further $61.1 million of expense is expected over a weighted-average 2.20 years. The 2025 tangible equity units carry a 6.50% annual cash payment rate and are mandatorily settleable in 4.7–5.9 million shares in November 2028.

Balance sheet and cash flow

Net intangible assets comprised patents/developed technologies of $210.263 million, customer relationships of $651.348 million, and trademarks/trade names of $32.299 million. Goodwill was $325.3 million in Automation Enabling Technologies and $1,106.6 million in Medical Solutions. The acquisition materially increased goodwill, intangibles and leverage; equity less goodwill and intangibles was negative $701.342 million. Accrued expenses and other current liabilities increased to $354.543 million, principally reflecting the milestone accrual. No goodwill impairment was found in the 2026 annual test.

Acquisition payments drove investing outflows. Senior-credit-facility borrowings were $626.0 million, repayments were $44.068 million, and net private-placement proceeds were $288.026 million. Cash declined by $231.653 million during 9M. Total debt includes $412.500 million outstanding on the revolver, $340.519 million of term loans and $85.620 million of tangible equity-unit notes, net of $8.813 million of unamortized debt costs. The company was covenant-compliant; permitted leverage is 4.00:1, temporarily 4.50:1 for four quarters after a designated acquisition. Facilities mature in June 2030 and are secured by substantially all assets.

Restructuring programs involve site closures and manufacturing regionalization, with substantial completion expected by Q1 2027 for the 2025 program. Novanta also expects a U.K. pension-plan buy-out in H2 2027 that could trigger a non-cash settlement charge.

NOVT — Item 2 MD&A

Business and revenue

Novanta supplies precision-technology solutions primarily to medical and advanced-industrial OEMs through Automation Enabling Technologies (AET) and Medical Solutions. For the nine months ended October 2, 2026, medical represented approximately 52% of revenue and advanced industrial 48%. The company is pursuing growth through product launches, deeper customer relationships, cross-selling and complementary acquisitions, while investing in applications such as robotics, laser processing, additive manufacturing, automation and metrology. It is also targeting margin and efficiency improvements through lean manufacturing, strategic sourcing, regionalized manufacturing and manufacturing centers of excellence.

Revenue increased 23.1% in Q3 and 14.7% for 9M. Riverpoint contributed $32.9M in Q3; the net contribution from 2026 and 2025 acquisitions was $41.9M for 9M. Excluding acquisitions, AET revenue grew 16.0% in Q3 and 11.5% for 9M; Medical Solutions grew 3.5% and 6.2%, respectively. Foreign exchange reduced Q3 revenue by $0.3M and added $10.3M for 9M. Q3 AET growth reflected robotics and automation sales up 17.3% and precision-manufacturing sales up 13.7%, supported by end-market demand and new products.

For 9M, AET revenue was $412.815M versus $370.154M (up 11.5%); Medical Solutions revenue was $415.707M versus $352.097M (up 18.1%, including acquisition contributions).

Margins, costs and earnings

Q3 gross margin was 44.5%, versus 44.8%; 9M margin was 44.7%, versus 44.6%. AET gross margin improved to 50.2% from 47.3% in Q3 and to 50.2% from 47.8% for 9M, helped by volume, pricing and cost improvements, with tariff-related benefits in the nine-month period. Inflation and factory redundancy costs partly offset those gains. Medical gross margin declined to 39.9% from 43.0% in Q3 and to 40.0% from 42.1% for 9M, primarily reflecting acquisition-related intangible amortization and temporary operational-transformation and factory redundancy costs.

Operating income fell 36.3% in Q3 and 14.0% for 9M. Q3 unallocated operating loss widened mainly because of acquisition-related costs; the 9M increase also reflected variable compensation. Q3 restructuring, acquisition and related costs were $23.086M versus $6.677M, including acquisition costs of $19.2M versus $1.5M. For 9M, those costs were $38.190M versus $16.794M, including acquisition-related costs of $28.1M versus $4.4M. Other Q3 operating expenses were R&D of $26.347M versus $24.090M, SG&A of $57.615M versus $51.378M, and purchased-intangible amortization of $14.679M versus $6.928M. Higher amortization, SG&A, R&D and acquisition costs more than offset higher gross profit.

Q3 net interest expense rose mainly because of acquisition-funded borrowing; the weighted-average senior-facility rate was 5.34%, versus 5.32%. For 9M, net interest expense decreased mainly due to higher interest income; the average rate was 5.58%, versus 5.48%. The Q3 effective tax rate increased to 68.2% from 32.4%, principally because acquisition transaction costs were nondeductible and Riverpoint changed the income mix; the 9M rate was 26.6% versus 24.2%. Lower Q3 net income and increased weighted-average shares following the private placement drove the EPS decline; 9M EPS was also affected by share dilution.

Acquisition, funding and liquidity

Novanta acquired Riverpoint Medical, a supplier of minimally invasive surgical consumables, on July 23, 2026, for $1,200.6M of upfront cash consideration, net of cash acquired. A further $250.0M milestone payment is due on or before January 8, 2027; its present-value liability was $246.5M at October 2, 2026, with the remaining discount to accrete to acquisition and related costs until payment. Riverpoint contributed $32.9M of Q3 revenue.

Operating cash flow rose primarily because of customer payments under a supply agreement, lower cash bonuses after 2025 bonuses were converted to equity, and lower cash taxes. Investing outflow principally reflected Riverpoint consideration. Financing inflows included $616.0M of Senior Credit Facility borrowings and $288.0M of net private-placement proceeds. Major financing outflows included $44.1M of debt repayments and $18.6M of share repurchases. Full-year 2026 capital expenditures are expected to be $30M–$40M, including a significant China capacity expansion.

At October 2, cash and equivalents were $149.218M, down from $380.871M at December 31, 2025; $111.3M was held outside Canada and the U.S. Unused and available Senior Credit Facility funds were $437.5M, versus $850.0M at year-end 2025. Management expects operating cash flows to cover operating and capital-expenditure needs for at least 12 months and cites the revolving facility as additional liquidity. The agreement permits a conditional accordion of up to $350.0M.

Facility borrowings comprised $67.2M (€59.7M) of Euro Term Loans, $273.3M of U.S. Term Loans and $412.5M under the revolver—$67.2M euro-denominated and $685.8M U.S.-dollar-denominated in total. The facilities mature in June 2030. At period-end, leverage was 2.43:1 against a 4.00:1 maximum, and fixed-charge coverage was 4.00:1 against a 1.25:1 minimum. The June 2026 amendment allows maximum leverage of 4.50:1 for four quarters after a designated acquisition, reduces the minimum fixed-charge coverage ratio to 1.00:1 for four quarters following the specified acquisition, and adds a 0.25% interest-margin increase if leverage exceeds 3.75:1. About $67.2M of facility borrowings were held in subsidiaries outside Canada and the U.S.

Capital structure, risks and outlook

The June 2026 private placement issued 2,142,857 common shares at $140 each—approximately 5.7% of shares outstanding immediately after closing. Gross proceeds were approximately $300M; after $12.0M of fees and expenses, net proceeds were $288.0M.

In November 2025, Novanta issued 12.65M 6.50% tangible equity units for $50 each, raising $632.5M gross and $613.0M net. Their stock purchase contracts settle automatically on November 1, 2028, delivering 0.3729–0.4662 common shares per contract, subject to market-value adjustments. The associated senior amortizing notes had $85.6M outstanding at October 2, 2026, with $8.74 principal per unit and 6.30% interest. During 9M 2026, the company repurchased 88,000 shares for $10.2M under its completed 2020 plan and 71,000 shares for $8.4M under its 2025 plan; $191.6M remained of that plan’s $200.0M authorization.

Risks include volatile OEM orders and customer concentration, product-development and transition execution, component shortages and inflation, rare-earth export-license requirements, tariffs and geopolitical/logistics disruption. The 2026 Iran conflict and temporary Strait of Hormuz closure added energy-price and supply-chain uncertainty; mitigation through suppliers, pricing and operations may not fully offset cost effects. Other significant exposures include Riverpoint integration and forecast accuracy, the milestone funding obligation, debt service and covenant compliance, refinancing and capital availability, medical-device approvals and recalls, cybersecurity, foreign exchange and interest rates. The company reported no material changes to critical accounting policies or estimates from its 2025 Form 10-K.

Market risk

For the nine months ended October 2, 2026, NOVT reported no material changes to the market-risk disclosures in its FY2025 Form 10-K, other than updated interest-rate exposure. Its primary market risks are foreign-exchange fluctuations and interest-rate sensitivity.

At October 2, 2026, NOVT had $753.0 million of variable-rate debt outstanding under its Senior Credit Facilities. A 100-basis-point increase in interest rates would increase annual pre-tax interest expense by approximately $7.5 million.

Disclosure Controls and Internal Controls

Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of October 2, 2026.

During the quarter, the company implemented a new financial and operating system at one site as part of a multi-year, phased rollout. The implementation involved changes to related processes and internal controls over financial reporting. Transitions at additional sites will continue, with steps being taken to preserve control effectiveness.

Following the July 23, 2026 acquisition of Riverpoint Medical, the company is integrating the acquired business into its internal control over financial reporting. The integration is expected to continue for 12 months. Management expects to exclude Riverpoint Medical from the company’s December 31, 2026 assessment of internal control over financial reporting, consistent with SEC staff guidance.

No other changes during the quarter materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Risk factors

The company reports no material changes to its risk factors from those described in its FY2025 Form 10-K, other than the risks discussed here.

Demand, economic cycles, and government policy

Demand depends substantially on customers’ capacity, productivity, quality, and investment initiatives. Economic weakness or political uncertainty could reduce capital spending and business activity, hurting revenue and gross margin. The company has experienced significant end-market cycles; microelectronics and industrial capital equipment are particularly exposed to oversupply and downturns in equipment demand, so orders and results in one period may not predict later periods. Changes in laws, tariffs, regulation, government funding, or enforcement could also constrain demand, including reductions in NIH or other federal research funding, grant or contract cancellations, and rules affecting life sciences and pharmaceutical customers.

Geopolitical disruption, inflation, and supply constraints

The escalation of the U.S., Israel, and Iran military conflict in February 2026 has contributed to global energy-supply disruption and higher energy prices, increasing supply-chain uncertainty, freight and commodity costs. Further effects could include higher component and raw-material costs, manufacturing inflation, weaker demand, currency and interest-rate volatility, and cyberattacks against the company or its business partners. The company cannot predict the conflict’s scope, duration, or ultimate business impact. It has raised prices in response to materials and component inflation, but customers may reject increases or the increases may not fully offset higher costs.

Some critical components and materials are available only from limited or single sources. Supplier disruption or price increases, or inability to find alternatives, could delay shipments, harm customer relationships, and cause lost orders. Certain Precision Manufacturing and Robotics and Automation products use rare-earth materials sourced in China and magnets made from them, for which Chinese government export licenses are required. The company has been unable for several months to obtain licenses for certain shipments, delaying customer orders and increasing manufacturing costs; continued restrictions or similar controls on other inputs could worsen fulfillment and cost pressures. Some businesses also buy components from suppliers that compete with other company businesses, creating a risk of price increases or reduced supply.

Acquisition execution and impairment exposure

The company expects acquisitions to broaden its products and services and has acquired Keonn Technologies, Motion Solutions, MPH Medical Devices, ATI Industrial Automation, Schneider Electric Motion USA, and Riverpoint Medical. Riverpoint, acquired in July 2026, is substantially larger than recent acquisitions. Consideration included $1,200.6 million of upfront cash, net of cash acquired, plus a $250.0 million milestone payment due on or before January 8, 2027.

Acquisitions entail integration demands and management distraction, and may be affected by limited integration resources, diligence shortcomings, weaker-than-expected revenue, higher costs, or unassumed or inadequately insured liabilities. These factors could prevent expected growth, synergies, and profitability, or result in losses and impairment.

As of October 2, 2026, net intangible assets, including goodwill, were $2,325.9 million, approximately 73% of total assets. They principally comprise goodwill, customer relationships, patents, trademarks, trade names, and core technologies. Goodwill and indefinite-lived intangibles are tested at least annually; other intangibles are assessed when impairment indicators arise. Riverpoint accounts for all of the increase in net intangible assets since December 31, 2025, increasing impairment exposure if anticipated growth or synergies are not achieved.

Financing, leverage, and dilution

At December 31, 2025, debt was $259.6 million: $149.0 million under the senior secured credit agreement and $110.6 million of senior amortizing notes associated with 6.50% tangible equity units. The revolving facility then had $850.0 million of additional borrowing capacity.

In June 2026, the company privately placed 2,142,857 common shares at $140.00 per share, generating approximately $300 million of gross proceeds, partly to fund Riverpoint. The shares’ resale was registered; actual or perceived public-market sales could pressure the share price and dilute existing holders. To fund part of Riverpoint, the company amended its credit agreement and borrowed approximately $616.0 million. As of October 2, 2026, debt was $753.0 million under the credit agreement and $838.6 million total outstanding.

Higher leverage increases vulnerability to downturns and higher interest rates on variable-rate debt, limits financial flexibility, and may constrain investment or further financing. Some foreign-held cash may not be immediately available for debt repayment. Credit-agreement covenants restrict certain activities, and an uncured or unwaived default could accelerate borrowings. Additional financing may be unavailable or costly; equity or convertible issuance could dilute shareholders, while the credit agreement restricts debt financing from other sources.

• The company reported no disclosures in lieu of Form 8-K and no material changes to its procedures for shareholder recommendations of director nominees.
• During the quarter ended October 2, 2026, CFO Robert J. Buckley adopted a Rule 10b5-1 trading plan on August 11, 2026, to sell 56,250 shares; the plan expires April 30, 2027. Chief Accounting Officer John J. Burke adopted a Rule 10b5-1 plan on August 18, 2026, to sell 4,000 shares; it expires August 20, 2027.
• No officers or directors adopted or terminated non-Rule 10b5-1 trading arrangements during the quarter. This section reports no financial results or business-operating developments.